OCRF Now Accepting Applications for 2016 Research Grants
OCRF Now Accepting Applications for 2016 Research Grants
We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015. Click here for more information.
News
Microenvironment Regulates Tumor Suppressor miRNA
Microenvironment Regulates Tumor Suppressor miRNA
(April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused methylation mediated decrease in the expression of miR-193b in the tumor cells. … Continued
Population Distribution of Lifetime Risk of Ovarian Cancer ...
Population Distribution of Lifetime Risk of Ovarian Cancer in the US
(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population. In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle factors. Leigh Pierce, PhD and … Continued
Intraperitoneal Chemo Associated with Long-Term Survival Ad...
Intraperitoneal Chemo Associated with Long-Term Survival Advantage
(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer. The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number … Continued
Decisions on a Knife-Edge: Risks and Benefits of Fallopian ...
Decisions on a Knife-Edge: Risks and Benefits of Fallopian Tube Removal
(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer. Removing only the fallopian tubes will avoid forcing a woman into early menopause, which is an appealing option for many women. Yet it’s not … Continued
Tailored Surgical Approach Leads to Better Outcomes in Ovar...
Tailored Surgical Approach Leads to Better Outcomes in Ovarian Cancer
(March 10, 2015) An algorithm developed at MD Anderson Cancer Center in Houston has dramatically increased complete resection rates in advanced ovarian cancer, giving patients the best possible chance of survival. The work was funded in part by an OCRF research grant to Anil Sood, MD. The results are summarized in an article in Nature … Continued
OCRF Research Finds New Therapeutic Strategy for Ovarian Ca...
OCRF Research Finds New Therapeutic Strategy for Ovarian Cancer
(February 17, 2015) OCRF-funded researchers at The Wistar Institute have identified a new therapeutic target in clear cell ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease. The findings were published online by the journal Nature Medicine. The research was made possible in part … Continued
New Tool Could Speed Development of Ovarian Cancer Drugs
New Tool Could Speed Development of Ovarian Cancer Drugs
(February 13, 2015) University of Chicago Medicine researchers, including OCRF grantee and Scientific Advisory Committee member Ernst Lengyel, MD, PhD, have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has … Continued
Ovarian Cancer Research Fund Awards Nearly $6.5 Million in ...
Ovarian Cancer Research Fund Awards Nearly $6.5 Million in Grants
Total investment in the field now over $65 million New York, NY February 11, 2015 — To conclude Ovarian Cancer Research Fund’s 20th anniversary year, $6.453 million has been awarded in scientific research grants for ovarian cancer and program grants to support gynecologic cancer patients. This brings OCRF’s total investment in research and related educational … Continued
Meet OCRF’s 2015 Grantees
Meet OCRF’s 2015 Grantees
(February 11, 2015) Ovarian Cancer Research Fund has announced that $6.1 million has been awarded in scientific research grants for ovarian cancer. This brings OCRF’s total investment in research and related educational and support initiatives to nearly $70 million. The twenty new OCRF research grants have been awarded to top scientists at fourteen leading medical centers across … Continued
SGI-110 is an Ovarian Cancer Chemosensitizer
SGI-110 is an Ovarian Cancer Chemosensitizer
(February 4, 2014) In research published last October in Clinical Cancer Research, a team of OCRF-funded investigators showed that a novel therapy can resentisize ovarian cancer to chemotherapy. The work was led by Dr. Kenneth Nephew, who was funded through an OCRF Program Project Development Grant. The development of resistance to chemotherapy in ovarian cancer … Continued
OCRF Research Identifies Six New Susceptibility Loci for Ov...
OCRF Research Identifies Six New Susceptibility Loci for Ovarian Cancer
(Feb. 3, 2015) An international study using data from the OCRF-funded Ovarian Cancer Association Consortium has found six new gene regions which increase a woman’s risk of ovarian cancer. The findings were published this month in Nature Communications. Previous studies have identified 12 epithelial ovarian cancer susceptibility alleles (an allele is one of two or … Continued
